|
Craven House Capital PLC on Tuesday noted that its investee Bio Vitos Medical Ltd is set to own 88% of medical technology company Hemcheck Sweden AB, after receiving conditional approval from Nasdaq Stockholm. The London-based investment fund, which has a minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses, said Bio Vitos will own 259.7 million shares in Hemcheck once the transaction is completed next month. Bio Vitos Medical Ltd, which specialises in vitamin supplements, first announced its intention to buy a shareholding in Hemcheck last month, but had to wait for Nasdaq approval. Craven said its 25% holding in Bio Vitos will not change. Shares in Craven were flat at $0.17 each in London on Tuesday afternoon. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
